Abstract
Background: The aim of this article was to review the association between androgen deprivation therapy (ADT) and the risk of stroke in patients with prostate cancer (PC). Thus, we performed this study to understand the impact of ADT on the incidence of stroke in PC patients. Methods: A comprehensive literature search was performed in June 2019 based on PubMed, EMBASE, and Web of science databases. Pooled rate ratio (RR), hazard ratio (HR), and their 95% confidence intervals (95% CIs) were calculated with a DerSimonian and Laird random effects. Result: A total of 239,099 patients from 10 studies were included in this analysis. There was no significant association in pooled RR analysis. Pooled HR analysis showed that ADT treatment increased the risk of stroke (HR = 1.129, 95% CI: 1.019–1.251, p = 0.02). In a subgroup analysis of RR results, we found that different ADT treatments had no significant effect on increasing the risk of stroke. And in the subgroup analysis of HR results, only PC patients treated with gonadotropin-releasing hormone (GnRH) agonists, orchiectomy, or oral antiandrogen had significantly higher risk of stroke. In addition, we observed the result from another comparison that PC patients treated with GnRH agonists combined with oral antiandrogens might have a lower risk of stroke compared with using GnRH agonists alone. Conclusion: Our results showed that GnRH agonists, orchiectomy, or oral antiandrogen might play an important role in the incidence of stroke. We still need further studies to clarify the role of ADT in the increased risk of stroke.
References
1.
Hussain
S
, Gunnell
D
, Donovan
J
, McPhail
S
, Hamdy
F
, Neal
D
, et al. Secular trends in prostate cancer mortality, incidence and treatment: england and Wales, 1975-2004
. BJU Int
. 2008
Mar
;101
(5
):547
–55
.
[PubMed]
1464-40962.
Bray
F
, Lortet-Tieulent
J
, Ferlay
J
, Forman
D
, Auvinen
A
. Prostate cancer incidence and mortality trends in 37 European countries: an overview
. Eur J Cancer
. 2010
Nov
;46
(17
):3040
–52
.
[PubMed]
0959-80493.
Badiozamani
KR
. Duration of androgen suppression in prostate cancer
. N Engl J Med
. 2009
Sep
;361
(12
):1212
–3
.
[PubMed]
0028-47934.
Walsh
PC
. Risk of fracture after androgen deprivation for prostate cancer
. J Urol
. 2005
Sep
;174
(3
):929
–30
.
[PubMed]
0022-53475.
Huang
G
, Yeung
CY
, Lee
KK
, Liu
J
, Ho
KL
, Yiu
MK
, et al. Androgen deprivation therapy and cardiovascular risk in chinese patients with nonmetastatic carcinoma of prostate
. J Oncol
. 2014
;2014
:529468
.
[PubMed]
1687-84506.
Ingeman
A
, Andersen
G
, Hundborg
HH
, Svendsen
ML
, Johnsen
SP
. In-hospital medical complications, length of stay, and mortality among stroke unit patients
. Stroke
. 2011
Nov
;42
(11
):3214
–8
.
[PubMed]
0039-24997.
Deka
R
, Simpson
DR
, Panizzon
MS
, Hauger
RL
, Riviere
P
, Nalawade
V
, et al. Stroke and thromboembolic events in men with prostate cancer treated with definitive radiation therapy with or without androgen deprivation therapy
. Prostate Cancer Prostatic Dis
. 2019
Apr
.
[PubMed]
1365-78528.
Teoh
JY
, Chiu
PK
, Chan
SY
, Poon
DM
, Cheung
HY
, Hou
SS
, et al. Risk of ischemic stroke after androgen deprivation therapy for prostate cancer in the Chinese population living in Hong Kong
. Jpn J Clin Oncol
. 2015
May
;45
(5
):483
–7
.
[PubMed]
0368-28119.
Tae
BS
, Jeon
BJ
, Choi
H
, Bae
JH
, Park
JY
. Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population-based propensity score matching study
. Cancer Med
. 2019
Aug
;8
(9
):4475
–83
.
[PubMed]
2045-763410.
Alibhai
SM
, Duong-Hua
M
, Sutradhar
R
, Fleshner
NE
, Warde
P
, Cheung
AM
, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes
. J Clin Oncol
. 2009
Jul
;27
(21
):3452
–8
.
[PubMed]
0732-183X11.
Chung
SD
, Chen
YK
, Wu
FJ
, Lin
HC
. Hormone therapy for prostate cancer and the risk of stroke: a 5-year follow-up study
. BJU Int
. 2012
Apr
;109
(7
):1001
–5
.
[PubMed]
1464-409612.
Keating
NL
, O’Malley
AJ
, Freedland
SJ
, Smith
MR
. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer
. J Natl Cancer Inst
. 2010
Jan
;102
(1
):39
–46
.
[PubMed]
0027-887413.
Jespersen
CG
, Nørgaard
M
, Borre
M
. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study
. Eur Urol
. 2014
Apr
;65
(4
):704
–9
.
[PubMed]
0302-283814.
Azoulay
L
, Yin
H
, Benayoun
S
, Renoux
C
, Boivin
JF
, Suissa
S
. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer
. Eur Urol
. 2011
Dec
;60
(6
):1244
–50
.
[PubMed]
0302-283815.
Van Hemelrijck
M
, Garmo
H
, Holmberg
L
, Ingelsson
E
, Bratt
O
, Bill-Axelson
A
, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden
. J Clin Oncol
. 2010
Jul
;28
(21
):3448
–56
.
[PubMed]
0732-183X16.
Svartberg
J
, von Mühlen
D
, Schirmer
H
, Barrett-Connor
E
, Sundfjord
J
, Jorde
R
. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromsø Study
. Eur J Endocrinol
. 2004
Jan
;150
(1
):65
–71
.
[PubMed]
0804-464317.
Traish
AM
, Saad
F
, Feeley
RJ
, Guay
A
. The dark side of testosterone deficiency: III. Cardiovascular disease
. J Androl
. 2009
Sep-Oct
;30
(5
):477
–94
.
[PubMed]
0196-363518.
Laughlin
GA
, Barrett-Connor
E
, Bergstrom
J
. Low serum testosterone and mortality in older men
. J Clin Endocrinol Metab
. 2008
Jan
;93
(1
):68
–75
.
[PubMed]
0021-972X19.
Isidori
AM
, Giannetta
E
, Greco
EA
, Gianfrilli
D
, Bonifacio
V
, Isidori
A
, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis
. Clin Endocrinol (Oxf)
. 2005
Sep
;63
(3
):280
–93
.
[PubMed]
0300-066420.
Glueck
CJ
, Glueck
HI
, Stroop
D
, Speirs
J
, Hamer
T
, Tracy
T
. Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men
. J Lab Clin Med
. 1993
Oct
;122
(4
):412
–20
.
[PubMed]
0022-214321.
Mårin
P
, Holmäng
S
, Gustafsson
C
, Jönsson
L
, Kvist
H
, Elander
A
, et al. Androgen treatment of abdominally obese men
. Obes Res
. 1993
Jul
;1
(4
):245
–51
.
[PubMed]
1071-732322.
Higgins
JP
, Thompson
SG
. Quantifying heterogeneity in a meta-analysis
. Stat Med
. 2002
Jun
;21
(11
):1539
–58
.
[PubMed]
0277-671523.
Bax
L
, Ikeda
N
, Fukui
N
, Yaju
Y
, Tsuruta
H
, Moons
KG
. More than numbers: the power of graphs in meta-analysis
. Am J Epidemiol
. 2009
Jan
;169
(2
):249
–55
.
[PubMed]
0002-926224.
Seagroatt
V
, Stratton
I
. Bias in meta-analysis detected by a simple, graphical test. Test had 10% false positive rate
. BMJ
. 1998
Feb
;316
(7129
):470
.
[PubMed]
0959-813825.
Yoo
S
, You
D
, Kim
YS
, Hong
JH
, Ahn
H
, Kim
CS
. Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy
. Urol Int
. 2017
;99
(4
):406
–13
.
[PubMed]
0042-113826.
Oliver
T
, Wilson
P
, Ansell
W
, Philp
T
, Chinegwundoh
F
, Shamash
J
, et al. A Prospective Audit of Intermittent Anti-Androgen verses Pituitary Blockade Suggests a Bipolar Androgen Type Strategy May Be Safe in Untreated Prostate Cancer
. Urol Int
. 2018
;100
(2
):172
–80
.
[PubMed]
0042-1138© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
